Glucocorticoid withdrawal - heterozygous carriers of congenital adrenal hyperplasia at risk?
F
F
Brackmann
H-G
HG
Dörr
C R
CR
Bartram
K
K
Hinderhofer
W
W
Holter
T
T
Langer
D000312:Adrenal Hyperplasia, Congenital / Q000175:diagnosis / Q000235:genetics*; D000324:Adrenocorticotropic Hormone; D047808:Adrenogenital Syndrome / Q000235:genetics*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002675:Child, Preschool; D004252:DNA Mutational Analysis; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D006580:Genetic Carrier Screening; D005817:Genetic Counseling; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007049:Iatrogenic Disease; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects*; D017422:Sequence Analysis, DNA; D013255:Steroid 21-Hydroxylase / Q000235:genetics*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000235:genetics*
D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; C531510:CYP21A2 protein, human; D013255:Steroid 21-Hydroxylase; D011241:Prednisone; D006854:Hydrocortisone